Lataa...
Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status
BACKGROUND: While reduction of accumulated body fluid using loop diuretics is a commonly used therapeutic option for acute heart failure (AHF), some patients, especially those with chronic kidney disease (CKD), show significantly poor treatment response to loop diuretics. Tolvaptan (TLV) has shown e...
Tallennettuna:
| Julkaisussa: | J Clin Med Res |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elmer Press
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6306139/ https://ncbi.nlm.nih.gov/pubmed/30627278 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3671 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|